# EDGAR Filing Document

**Accession Number:** 0000882796
**File Stem:** 0001171843-26-000405
**Filing Date:** 2026-1
**Character Count:** 5411
**Document Hash:** fd0aacb46bf5ee747208d9096a5baec8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-000405.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001171843-26-000405

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251014

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOCRYST PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0000882796
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 621413174
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-23186
- **FILM NUMBER:** 26556934

**BUSINESS ADDRESS:**
- **STREET 1:** 4505 EMPEROR BOULEVARD
- **STREET 2:** SUITE 200
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-859-1302

**MAIL ADDRESS:**
- **STREET 1:** 4505 EMPEROR BOULEVARD
- **STREET 2:** SUITE 200
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

FORM 8-K/A

(Amendment No. 1)

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 14, 2025

**BioCryst Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-23186** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**62-1413174** |
| (State or Other Jurisdiction | (Commission | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IRS Employer |
| of Incorporation) | File Number) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identification No.) |

---

**4505 Emperor Blvd., Suite 200**

**Durham, North Carolina 27703**

(Address of Principal Executive Offices) (Zip Code)

 **(919) 859-1302**

(Registrant's telephone number, including area code)

________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock** | **BCRX** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 23, 2026 (the "<u>Closing Date</u>"), BioCryst Pharmaceuticals, Inc., a Delaware corporation ("<u>BioCryst</u>") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the "<u>Merger Agreement</u>"), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("<u>Merger Sub</u>") and Astria Therapeutics, Inc., a Delaware corporation ("<u>Astria</u>"). On the Closing Date, Merger Sub merged with and into Astria (the "<u>Merger</u>"), with Astria surviving the Merger as a wholly owned subsidiary of BioCryst.

On October 14, 2025, BioCryst filed a Current Report on Form 8-K (the "<u>Initial 8-K</u>") regarding the appointment of Jill C. Milne, Ph.D. to its board of directors (the "<u>Board</u>"), subject to certain conditions specified in the Merger Agreement. On the Closing Date, such conditions were satisfied and Dr. Milne's appointment to the Board became effective. This Amendment No. 1 to the Initial 8-K is being filed to report that on January 20, 2026, the Board appointed Dr. Milne as a member of its Compensation and Science Committees, effective as of the Closing Date.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 23, 2026 | **BioCryst Pharmaceuticals, Inc.** | **BioCryst Pharmaceuticals, Inc.** |
|  | <br>By: | <br>/s/ Alane Barnes |
|  |  | Alane Barnes |
|  |  | Chief Legal Officer |

---